Overview

Trial for Treatment Refractory Trigeminal Neuralgia

Status:
Recruiting
Trial end date:
2021-12-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
Phase:
Phase 2
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.